BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flashner-Abramson E, Vasudevan S, Adejumobi IA, Sonnenblick A, Kravchenko-Balasha N. Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy. Theranostics 2019;9:5149-65. [PMID: 31410207 DOI: 10.7150/thno.31657] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Jubran MR, Rubinstein AM, Cojocari I, Adejumobi IA, Mogilevsky M, Tibi S, Sionov RV, Verreault M, Idbaih A, Karni R, Kravchenko-Balasha N. Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading. Oncogenesis 2020;9:11. [PMID: 32024816 DOI: 10.1038/s41389-020-0199-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Cardillo TM, Rossi DL, Zalath MB, Liu D, Arrojo R, Sharkey RM, Chang CH, Goldenberg DM. Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget 2020;11:3849-62. [PMID: 33196706 DOI: 10.18632/oncotarget.27766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Dagan H, Flashner-Abramson E, Vasudevan S, Jubran MR, Cohen E, Kravchenko-Balasha N. Exploring Alzheimer's Disease Molecular Variability via Calculation of Personalized Transcriptional Signatures. Biomolecules 2020;10:E503. [PMID: 32225014 DOI: 10.3390/biom10040503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Cava C, Sabetian S, Castiglioni I. Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data. Entropy (Basel) 2021;23:225. [PMID: 33670375 DOI: 10.3390/e23020225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Vasudevan S, Flashner-Abramson E, Alkhatib H, Roy Chowdhury S, Adejumobi IA, Vilenski D, Stefansky S, Rubinstein AM, Kravchenko-Balasha N. Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations. NPJ Precis Oncol 2021;5:50. [PMID: 34112933 DOI: 10.1038/s41698-021-00190-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Kravchenko-Balasha N. Translating Cancer Molecular Variability into Personalized Information Using Bulk and Single Cell Approaches. Proteomics 2020;20:e1900227. [PMID: 32072740 DOI: 10.1002/pmic.201900227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vasudevan S, Adejumobi IA, Alkhatib H, Roy Chowdhury S, Stefansky S, Rubinstein AM, Kravchenko-Balasha N. Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures. Cancers (Basel) 2021;13:5009. [PMID: 34638492 DOI: 10.3390/cancers13195009] [Reference Citation Analysis]
8 Sharon S, Duhen T, Bambina S, Baird J, Leidner R, Bell B, Casap N, Crittenden M, Vasudevan S, Jubran M, Kravchenko-Balasha N, Gough M. Explant Modeling of the Immune Environment of Head and Neck Cancer. Front Oncol 2021;11:611365. [PMID: 34221953 DOI: 10.3389/fonc.2021.611365] [Reference Citation Analysis]
9 Zhang J, Du Q, Song X, Gao S, Pang X, Li Y, Zhang R, Abliz Z, He J. Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging. Theranostics 2020;10:2621-30. [PMID: 32194824 DOI: 10.7150/thno.41763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]